Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

TickerLGNDVenueUSSectorHealthcarePrimary listingBeta0.98
$310.1+1.20%
FinScore61

Ligand Pharmaceuticals Incorporated is a United States-based company in the Healthcare sector with a market capitalisation of $6.1B. Its FinScore is 61/100; its highest-scoring layer is Momentum (80) and its lowest is Value (32). The shares trade at 31.0x trailing earnings and are up 61% year to date.

Market cap
$6.1B
P/E (TTM)
31.0x
ROE
20.1%

Share price performance

Loading chart…

About Ligand Pharmaceuticals Incorporated

www.ligand.com

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Profile
Sector
Healthcare
Industry
Biotechnology
HQ
United States
Fiscal year-end
December
Trading currency
USD
Reporting currency
USD
Fundamentals updated
76 days ago
Market
Market cap
$6.1B
Shares outstanding
19.9M
P/E (TTM)
31.0x
Beta (issuer)
1.01
Revenue (latest FY)
$268.1M

Revenue breakdown

Revenue split not available

FinScore

As of 2026-10-21
Overall61
Quality65
Growth62
Value32
Momentum80
Relative Strength78

Snapshot

Ownership

As of 2026-06-30
Institutional
100.0%
Insider
0.9%
Free float
97.8%
Top-5 institutional holders
37.0%
Shares outstanding
19.9M
Sign up to see the top holders

Sign up or log in to see Analysis

Analysis for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Financials

Financials for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Estimates

Estimates for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Peers

Peers for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Valuation

Valuation for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see News

News for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.